This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Rigrodsky & Long, P.A. Announces Class Action Lawsuit Against AspenBio Pharma, Inc.

Rigrodsky & Long, P.A. announces that a class action lawsuit has been filed in the United States District Court for the Central District of California on behalf of all persons or entities who purchased or otherwise acquired the common stock of AspenBio Pharma, Inc. (“AspenBio Pharma” or the “Company”) (Nasdaq: APPY) between February 22, 2007 and July 19, 2010, inclusive (the “Class Period”), alleging violations of the Securities Exchange Act of 1934 (the “Complaint”).

The Complaint names AspenBio Pharma and certain of the Company’s current and former executive officers and directors as defendants. AspenBio Pharma is a bio-pharmaceutical company, engaged in the discovery, development, and commercialization of products that address un-met diagnostic and therapeutic needs. Its lead products include AppyScore, a blood-based diagnostic test that evaluates patients suspected of having acute appendicitis for use in diagnosing appendicitis in the hospital emergency department setting.

The Complaint alleges that during the Class Period, defendants made materially false and misleading statements, and/or omitted material facts, concerning the efficacy of AppyScore, which was then undergoing clinical trial. It is alleged that AspenBio claimed that the AppyScore product was: (1) highly effective at detecting patients with a wide spectrum of different severities of appendicitis; (2) utterly unique and unprecedented in its targeted market; (3) extremely helpful in the emergency room context; and (4) able to reduce the incidence of appendicitis related false-positives and unnecessary surgeries.

On July 19, 2010, however, the Company announced that the clinical trial had shown that AppyScore possessed considerably lower specificity than predicted. As a result of these two disclosures, the price of AspenBio Pharma stock first fell from a close of $3.38 on June 4, 2010 to a close of $1.57 on June 7, 2010, and then from a close of $0.97 on July 19, 2010 to a close of $0.69 on July 20, 2010.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free


Chart of I:DJI
DOW 17,798.49 -14.90 -0.08%
S&P 500 2,090.11 +1.24 0.06%
NASDAQ 5,127.5250 +11.3820 0.22%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs